Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024

AZYO 10.29.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-14
Name of Upcoming Event:Earnings Call
Full Press ReleaseSEC FilingsOur AZYO Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand
  • 01.06.2025 - Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners
  • 12.02.2024 - Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

Recent Filings

  • 12.11.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.14.2024 - EX-99.1 EX-99.1
  • 11.14.2024 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors

SILVER SPRING, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

The conference call can be accessed using the following information.

Webcast:Click hereU.S. Investors:877-407-8029International Investors:201-689-8029Conference ID:13749386

Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website athttp://investors.elutia.com/.

About ElutiaElutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visitwww.Elutia.com.

Investors:Matt SteinbergFINN Partnersmatt.steinberg@finnpartners.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com